Related Experiment Video

Updated: Jul 21, 2026

Targeted RNA Sequencing Assay to Characterize Gene Expression and Genomic Alterations
11:52

Targeted RNA Sequencing Assay to Characterize Gene Expression and Genomic Alterations

Published on: August 4, 2016

10.3K

Molecular analysis of non-small cell lung cancer using a dual-targeted DNA and RNA comprehensive genomic profiling

Hidenori Kage1, Shinji Kohsaka2, Kenji Tatsuno3

  • 1The Department of Respiratory Medicine, The University of Tokyo, 7-3-1 Hongo Bunkyo-ku, Tokyo, 113-8655, Japan.

Respiratory Investigation
|August 10, 2024
PubMed
Abstract

Insights

The Todai OncoPanel effectively identified actionable genomic alterations in non-small cell lung cancer (NSCLC), including druggable targets and potential for sensitive detection of MET exon 14 skipping using its RNA panel.

Area of Science:

  • Genomic Medicine
  • Oncology
  • Molecular Diagnostics

Background:

  • Comprehensive cancer genomic profiling guides treatment decisions.
  • Current tests analyze DNA from tissue or plasma for hundreds of genes.
  • RNA panels detect fusions and exon skipping, complementing DNA analysis.

Purpose of the Study:

  • To evaluate the Todai OncoPanel, a DNA and RNA targeted sequencing panel, for comprehensive genomic profiling of non-small cell lung cancer (NSCLC).
  • To identify actionable genomic alterations and assess the panel's sensitivity for detecting specific mutations like MET exon 14 skipping.

Main Methods:

  • Analyzed 60 NSCLC samples using the Todai OncoPanel (DNA and RNA) between April 2017 and March 2022.
  • Utilized matched tumor/normal pairs for analysis.
  • Downloaded publicly available genomic data from a cancer genomics database for comparison.

Main Results:

  • TP53 loss-of-function mutations (53%) and EGFR/ERBB2 activating mutations (33%/12% in adenocarcinoma) were detected by the DNA panel.
  • The RNA panel identified 11 fusion genes (all in adenocarcinoma) and detected MET exon 14 skipping in 7% of NSCLC samples.
  • A significantly higher prevalence of MET exon 14 splice site mutations was observed in the public database (2%) compared to the study cohort (p=0.039).

Conclusions:

  • The Todai OncoPanel successfully identified numerous druggable targets in NSCLC.
  • The RNA component of the panel demonstrates high sensitivity for detecting MET exon 14 skipping.
  • This comprehensive profiling approach aids in identifying potential therapeutic strategies for NSCLC patients.
Keywords:
Biomarker testingComprehensive genomic profilingGenomic testingLung cancerMET exon 14 skipping

More Related Videos

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction10:35

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

10.3K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.0K

Related Concept Videos

DNA Microarrays02:34

DNA Microarrays

Microarrays are high-throughput and relatively inexpensive assays that can be automated to analyze large quantities of data at a time. They are used in genome-wide studies to compare gene or protein expression under two varied conditions, such as healthy and diseased states. Microarrays consist of glass or silica slides on which probe molecules are covalently attached through surface functionalization. Most commonly, the slides are prepared through the chemisorption of silanes to silica...